Article Text

AB1020 Evaluation of the Disease Course of Italian Children with Juvenile Idiopathic Arthritis Treated with Etanercept: Preliminary Results in 1019 Patients
  1. S. Davì1,
  2. S. Verazza1,
  3. A. Consolaro1,
  4. A. Insalaco2,
  5. V. Gerloni3,
  6. R. Cimaz4,
  7. F. Zulian5,
  8. L. Lepore6,
  9. F. Corona7,
  10. G. Conti8,
  11. P. Barone9,
  12. M. Cattalini10,
  13. E. Cortis11,
  14. L. Breda12,
  15. A.N. Olivieri13,
  16. A. Civino14,
  17. D. Rigante15,
  18. F. La Torre16,
  19. G. D'Angelo17,
  20. R. Gallizzi18,
  21. M.C. Maggio19,
  22. R. Consolini20,
  23. A. De Fanti21,
  24. M.G. Alpigiani1,
  25. A. Martini1,22,
  26. A. Ravelli1,22
  1. 1Istituto Giannina Gaslini, Genova
  2. 2Ospedale Bambin Gesù, Roma
  3. 3Istituto Gaetano Pini, Milano
  4. 4Az.Ospedaliera-Universitaria Meyer, Firenze
  5. 5Ospedale Salus Pueri, Padova
  6. 6IRCCS Burlo Garofolo, Trieste
  7. 7IRCCS Ca' Granda-Ospedale Maggiore Policlinico, Milano
  8. 8Policlinico di Messina, Messina
  9. 9Policlinico-Università di Catania, Catania
  10. 10Clinica Pediatrica dell'Università di Brescia, Brescia
  11. 11Ospedale Santa Maria Della Stella, Orvieto
  12. 1212Policlinico-Università di Chieti, Chieti
  13. 13Seconda Università degli Studi di Napoli, Napoli
  14. 14Az. Ospedaliera di Tricase, Tricase
  15. 15Policlinico Gemell, Roma
  16. 16Ospedale Perrino, Brindisi
  17. 17Az. Ospedaliera delle Marche, Ancona
  18. 18Università di Messina, Messina
  19. 19Ospedale dei Bambini, Palermo
  20. 20Ospedale Santa Chiara, Università di Pisa, Pisa
  21. 2121Az. Ospedaliera S. Maria Nuova di Reggio Emilia, Reggio Emilia
  22. 22Università di Genova, Genova, Italy


Background The advent of biologic medications has considerably increased the potential for treatment benefit in juvenile idiopathic arthritis (JIA), with clinical remission being now achievable in a substantial proportion of patients.

Objectives To evaluate the outcome of etanercept (ETN) therapy in Italian children with JIA.

Methods This is a multicenter, observational study that includes all children with JIA who were given ETN at Italian pediatric rheumatology centers after January 2000. Patients were classified in 2 groups: patients who were no longer taking ETN at study start (Group 1); patients who were still receiving ETN at study start (Group 2). Patients in Group 1 underwent only retrospective assessments, whereas patients in Group 2 underwent both retrospective and cross-sectional assessments. The primary outcome of the study were reasons for ETN discontinuation in patients in Group 1, and achievement of the states of inactive disease (ID), minimal disease activity (MDA) and parent- and child-acceptable symptom state (PASS, CASS) in patients in Group 2. The above states were assessed through both formal definitions and JADAS cutoffs. The secondary outcome was the evaluation of frequency and characteristics of ETN-related side effects.

Results So far, the data of 1019 patients (629 in Group 1 and 390 in Group 2) have been collected. Among the 629 patients in Group 1, reasons for ETN discontinuation evaluated in 460 patients included disease remission (48.5%), lack of efficacy (26.1%), and side effects (14.8%). The results of assessment of disease state through formal definitions in 371 children of the 390 children in Group 2 who had already undergone the cross-sectional evaluation were the following: ID 39.7%, MDA 63.0%, PASS 82.4%, CASS 75.8%. The percentages of patients who reached the same disease states assessed through JADAS cutoffs were: ID 45.9%, MDA 61.6%, PASS 70.0%, CASS 66.2%. Serious adverse events were seen in 17 patients and included inflammatory bowel disease (8 pts), tuberculosis (1 pt), CMV hepatitis (1 pt), recurrent pneumoniae (1 pt), varicella complicated by bronchopneumonia (1 pt), acute pancreatitis (1pt), bacterial osteomyelitis (1 pt), bladder carcinoma (1pt), thyroid carcinoma (1 pt); 1 patient died of sepsis.

Conclusions A substantial proportion of children currently receiving ETN were in the states of ID or MDA, or were satisfied with treatment outcome. Half of the patients who had been discontinued from ETN before study start had the medication stopped because of disease remission. Serious adverse events were uncommon.

Disclosure of Interest None declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.